Loading stock data…
$5.40-0.09 (-1.64%)
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States.
Shattuck Labs, Inc. in the Healthcare sector is trading at $5.40 with a market capitalization of $597M. Wall Street consensus targets $15.40 (10 analysts), implying a +185.2% move over the next 12 months. The stock is currently 35% below its 52-week high of $8.33, remaining 9.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0↓ | $1.00M | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$16.16M↓ | -$15.54M↓ | -$13.37M↓ | -$10.72M↑ | -$13.03M |
| Net Income | -$15.15M↓ | -$14.77M↓ | -$12.59M↓ | -$10.06M↑ | -$12.46M |
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monocl...